Astrocyte Pharma Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 27

Astrocyte Pharma General Information

Description

Developer of neuroprotective therapies designed to advance treatment for brain injuries and neurodegenerative disorders. The company's technology targets astrocyte activation and utilizes adenosine receptor agonism to enhance brain resilience, enabling the healthcare sector to improve recovery outcomes for patients with stroke and traumatic brain injury.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 93 Shennecossett Road
  • Groton, CT 06340
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 93 Shennecossett Road
  • Groton, CT 06340
  • United States
+1 (617)

Astrocyte Pharma Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Astrocyte Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Secondary Transaction - Private 01-Aug-2026 Completed Clinical Trials - Phase 2
11. Later Stage VC (Series B2) 15-May-2026 Completed Clinical Trials - Phase 2
10. Grant 17-Jun-2025 Completed Clinical Trials - Phase 2
9. Debt - General 16-Dec-2024 Completed Clinical Trials - Phase 1
8. Later Stage VC 18-Aug-2023 Completed Clinical Trials - Phase 1
7. Grant 01-Jan-2023 Completed Clinical Trials - Phase 1
6. Grant 08-Sep-2021 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series A) 30-Apr-2021 Completed Clinical Trials - Phase 1
4. Grant 19-Sep-2018 $3.29M $2.42M Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 01-May-2018 $2.42M Completed Startup
To view Astrocyte Pharma’s complete valuation and funding history, request access »

Astrocyte Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series A 24,324,450 $0.000100 8% $0.38 $0.38 1x $0.38 21.32%
Seed 9,263,621 $0.000100 8% $0.27 $0.27 1x $0.27 8.12%
To view Astrocyte Pharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Astrocyte Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of neuroprotective therapies designed to advance treatment for brain injuries and neurodegenerative disorders.
Drug Discovery
Groton, CT
9 As of 2022

Toronto, Canada
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Astrocyte Pharma Competitors (66)

One of Astrocyte Pharma’s 66 competitors is Lucid Psycheceuticals, a Corporate Backed or Acquired company based in Toronto, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lucid Psycheceuticals Corporate Backed or Acquired Toronto, Canada
CervoMed Formerly VC-backed Boston, MA
Ischemix Formerly VC-backed Grafton, MA
Metabolic Solutions Development Company Venture Capital-Backed Kalamazoo, MI
Cytokinetics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 66 competitors. Get the full list »

Astrocyte Pharma Patents

Astrocyte Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4611724-A1 Compositions for intravenous administration Pending 03-Nov-2022
EP-4611724-A4 Compositions for intravenous administration Pending 03-Nov-2022
WO-2024097387-A1 Compositions for intravenous administration Inactive 03-Nov-2022
EP-4611765-A2 Fast-dissolving dosage forms and uses thereof Pending 03-Nov-2022
EP-4611765-A4 Fast-dissolving dosage forms and uses thereof Pending 03-Nov-2022 A61K31/7076
To view Astrocyte Pharma’s complete patent history, request access »

Astrocyte Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Astrocyte Pharma Investors (27)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel Star Ventures Angel Group Minority
Dynagrow Capital Venture Capital Minority
WaterStar Capital Venture Capital Minority
National Institutes of Health Government
Chemical Angel Network Angel Group
You’re viewing 5 of 27 investors. Get the full list »

Astrocyte Pharma FAQs

  • When was Astrocyte Pharma founded?

    Astrocyte Pharma was founded in 2014.

  • Where is Astrocyte Pharma headquartered?

    Astrocyte Pharma is headquartered in Groton, CT.

  • What is the size of Astrocyte Pharma?

    Astrocyte Pharma has 9 total employees.

  • What industry is Astrocyte Pharma in?

    Astrocyte Pharma’s primary industry is Drug Discovery.

  • Is Astrocyte Pharma a private or public company?

    Astrocyte Pharma is a Private company.

  • What is Astrocyte Pharma’s current revenue?

    The current revenue for Astrocyte Pharma is .

  • How much funding has Astrocyte Pharma raised over time?

    Astrocyte Pharma has raised $26.1M.

  • Who are Astrocyte Pharma’s investors?

    Angel Star Ventures, Dynagrow Capital, WaterStar Capital, National Institutes of Health, and Chemical Angel Network are 5 of 27 investors who have invested in Astrocyte Pharma.

  • Who are Astrocyte Pharma’s competitors?

    Lucid Psycheceuticals, CervoMed, Ischemix, Metabolic Solutions Development Company, and Cytokinetics are some of the 66 competitors of Astrocyte Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process